Literature DB >> 1452496

In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.

C J Pallister1, E M Johnson, D W Warnock, P J Elliot, D F Reeves.   

Abstract

Liposomal amphotericin B (AmBisome), at concentrations > or = 20 mg/L, and amphotericin B-deoxycholate (DC) (Fungizone), at concentrations > or = 1 mg/L, both caused a significant reduction in neutrophil uptake of Candida albicans blastospores following simultaneous addition of the drug with the blastospores. The reduction in uptake was seen also in tests in which blastospores were pre-treated with the drugs for 60 min, but was not detected in tests in which neutrophils were pre-treated for 60 min. Neither formulation affected neutrophil killing of C. albicans blastospores following simultaneous addition of the drug with the blastospores. However, previous treatment of the neutrophils with either formulation at a concentration of 20 mg/L led to enhanced killing of ingested blastospores. The results suggest that much higher concentrations of liposomal amphotericin B (AmBisome) are required to produce deleterious effects on neutrophil phagocytic function than with the conventional formulation of the drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452496     DOI: 10.1093/jac/30.3.313

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

2.  Reduction of no synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers.

Authors:  M Larabi; P Legrand; M Appel; S Gil; M Lepoivre; J Devissaguet; F Puisieux; G Barratt
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 3.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 4.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

5.  Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes.

Authors:  T Vago; G Baldi; D Colombo; M Barbareschi; G Norbiato; F Dallegri; M Bevilacqua
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 6.  Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Authors:  Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann; Bart J A Rijnders; Andreas H Groll; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

7.  Influence of amphotericin B and amphotericin B colloidal dispersion on the functions of human phagocytes in defence against Aspergillus species.

Authors:  S Perkhofer; G Blum; C Speth; A Mayr; M P Dierich; C Lass-Flörl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-06       Impact factor: 5.103

8.  Effect of the Ethyl Acetate Fraction of Eugenia uniflora on Proteins Global Expression during Morphogenesis in Candida albicans.

Authors:  Walicyranison P Silva-Rocha; Matheus F de Azevedo; Magda R A Ferreira; Julhiany de Fátima da Silva; Terezinha I E Svidzinski; Eveline P Milan; Luiz A L Soares; Keyla B F Rocha; Adriana F Uchôa; Maria J S Mendes-Giannini; Ana M Fusco Almeida; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-09-26       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.